Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer

PURPOSE: AZD1775 (adavosertib) is an inhibitor of the Wee1 kinase. In this study, we built on our preclinical studies to evaluate the safety and efficacy of AZD1775 in combination with gemcitabine and radiation in patients with newly diagnosed locally advanced pancreatic cancer. PATIENTS AND METHODS...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Cuneo, Kyle C., Morgan, Meredith A., Sahai, Vaibhav, Schipper, Matthew J., Parsels, Leslie A., Parsels, Joshua D., Devasia, Theresa, Al-Hawaray, Mahmoud, Cho, Clifford S., Nathan, Hari, Maybaum, Jonathan, Zalupski, Mark M., Lawrence, Theodore S.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2019
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7006846/
https://ncbi.nlm.nih.gov/pubmed/31398082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00730
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items